PMID- 23612920
OWN - NLM
STAT- MEDLINE
DCOM- 20140318
LR  - 20211021
IS  - 1861-0692 (Electronic)
IS  - 1861-0684 (Linking)
VI  - 102
IP  - 9
DP  - 2013 Sep
TI  - Impact of intracoronary reinfusion of bone marrow-derived mononuclear progenitor 
      cells on cardiopulmonary exercise capacity in patients with chronic 
      postinfarction heart failure.
PG  - 619-25
LID - 10.1007/s00392-013-0574-1 [doi]
AB  - INTRODUCTION: Intracoronary infusion of bone marrow-derived progenitor cells 
      (BMC) in patients with chronic ischaemic heart failure (CHF) is associated with 
      improvement in left ventricular ejection fraction (LVEF), reduction of NT-proBNP 
      levels and improved prognosis. However, effects of this therapy on 
      cardiopulmonary exercise capacity have not been investigated separately so far. 
      PATIENTS AND METHODS: One hundred and fifty-four patients with ischaemic heart 
      failure (mean LVEF 40.3 +/- 10.9 %, NT-proBNP 1,103 +/- 1,436 pg/ml) underwent 
      cardiopulmonary exercise capacity testing (CPX) before and 3 months after 
      intracoronary infusion of autologous BMC. Thirty patients with a potential bias 
      on the CPX course as concomitant coronary intervention, bypass surgery, new onset 
      of arrhythmias or implantation of cardiac resynchronization devices were excluded 
      from further analysis. RESULTS: The remaining 124 patients showed an increase in 
      exercise time and peak workload by 16.8 and 6 %. Peak oxygen uptake and oxygen 
      uptake efficiency slope also improved by 2.9 and 12.9 %, whereas other parameters 
      like peak oxygen pulse and the slope of minute ventilation versus CO2 elimination 
      remained unchanged. Analysis of patients with poor, moderate and conserved CPX 
      results prior to cell therapy documented that patients in tertiles with lowest 
      initial exercise capacity showed the largest improvements in CPX after therapy. 
      The differences in response to cell therapy were detectable in all investigated 
      CPX parameters and became significant for exercise time, peak oxygen uptake and 
      peak oxygen pulse. These findings indicate that intracoronary BMC therapy 
      improves exercise capacity in CHF patients with more advanced heart failure.
FAU - Honold, Joerg
AU  - Honold J
AD  - Medizinische Klinik III/Kardiologie, Klinikum Goethe-Universitat, 
      Theodor-Stern-Kai 7, 60590 Frankfurt, Germany.
FAU - Fischer-Rasokat, Ulrich
AU  - Fischer-Rasokat U
FAU - Seeger, Florian H
AU  - Seeger FH
FAU - Leistner, David
AU  - Leistner D
FAU - Lotz, Saskia
AU  - Lotz S
FAU - Dimmeler, Stefanie
AU  - Dimmeler S
FAU - Zeiher, Andreas M
AU  - Zeiher AM
FAU - Assmus, Birgit
AU  - Assmus B
LA  - eng
SI  - ClinicalTrials.gov/NCT00962364
PT  - Journal Article
DEP - 20130424
PL  - Germany
TA  - Clin Res Cardiol
JT  - Clinical research in cardiology : official journal of the German Cardiac Society
JID - 101264123
RN  - 0 (Biomarkers)
RN  - 0 (Peptide Fragments)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Exercise Test
MH  - *Exercise Tolerance
MH  - Female
MH  - Heart Failure/blood/diagnosis/etiology/physiopathology/*surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Myocardial Infarction/*complications
MH  - Natriuretic Peptide, Brain/blood
MH  - Oxygen Consumption
MH  - Peptide Fragments/blood
MH  - Randomized Controlled Trials as Topic
MH  - Recovery of Function
MH  - Registries
MH  - Retrospective Studies
MH  - *Stem Cell Transplantation
MH  - Stroke Volume
MH  - Time Factors
MH  - Treatment Outcome
MH  - Ventricular Function, Left
EDAT- 2013/04/25 06:00
MHDA- 2014/03/19 06:00
CRDT- 2013/04/25 06:00
PHST- 2013/04/02 00:00 [received]
PHST- 2013/04/18 00:00 [accepted]
PHST- 2013/04/25 06:00 [entrez]
PHST- 2013/04/25 06:00 [pubmed]
PHST- 2014/03/19 06:00 [medline]
AID - 10.1007/s00392-013-0574-1 [doi]
PST - ppublish
SO  - Clin Res Cardiol. 2013 Sep;102(9):619-25. doi: 10.1007/s00392-013-0574-1. Epub 
      2013 Apr 24.